Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the shares of Allergy Therapeutics plc. On August 16, 2023, the trader made purchases and sales of the company's 0.1p ordinary shares. The trader purchased 0 securities and sold 15,551 securities at a price of 0.0254 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. No indemnity or option arrangements, agreements, or understandings relating to relevant securities were disclosed. The disclosure was made in accordance with Rule 8 of the Takeover Code.